AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1

Q3 2015 13F Holders as of 30 Sep 2015

Type / Class
Debt / NOTE 2.000% 8/1
Number of holders
29
Total 13F principal, excl. options
291,967,500
Principal change
+259,033,500
Total reported value, excl. options
$220,710,621
Value change
+$196,009,621
Number of buys
28
Price
$0.7530

Significant Holders of AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q3 2015

29 filings reported holding 00767EAB8 - AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q3 2015.
AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 has 29 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of $291,967,500 of principal .
Largest 10 bondholders include HIGHBRIDGE CAPITAL MANAGEMENT LLC ($42,500,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($32,934,000 of principal), AMERIPRISE FINANCIAL INC ($31,870,000 of principal), Allianz Asset Management AG ($28,680,000 of principal), BAKER BROS. ADVISORS LP ($26,517,000 of principal), CITADEL ADVISORS LLC ($20,000,000 of principal), ZAZOVE ASSOCIATES LLC ($16,360,000 of principal), UBS OCONNOR LLC ($15,000,000 of principal), PUTNAM INVESTMENTS LLC ($13,032,000 of principal), and CITIGROUP INC ($10,560,000 of principal).
This table shows the top 29 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.